PIRS Pieris Pharmaceuticals Inc.

3.95
+0.05  (+1%)
Previous Close 3.9
Open 4.05
Price To Book 10.13
Market Cap 195,101,189
Shares 49,392,706
Volume 1,124,544
Short Ratio
Av. Daily Volume 767,041
Stock charts supplied by TradingView

NewsSee all news

  1. Pieris Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    Company to Host an Investor Conference Call On Monday, November 11, 2019 At 8:00 AM ESTBOSTON, MA / ACCESSWIRE / November 11, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company

  2. Pieris Pharmaceuticals Presents Data Demonstrating Monotherapy Clinical Benefit with 4-1BB/HER2 Bispecific PRS-343 in Phase 1 Escalation Study at the Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting

    BOSTON, MA / ACCESSWIRE / November 9, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform

  3. Pieris Pharmaceuticals to Host R&D Event

    BOSTON, MA / ACCESSWIRE / November 7, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform

  4. Pieris Pharmaceuticals to Present Phase 1 Data for 4-1BB/HER2 Bispecific PRS-343 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

    BOSTON, MA / ACCESSWIRE / November 5, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform

  5. Pieris Pharmaceuticals Announces $32 Million Private Placement and Potential Funding Mechanism for PRS-060 Co-development Opt-in

    BOSTON, MA / ACCESSWIRE / November 4, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2a data presented at EHA June 16, 2019.
PRS-080
Anemia of chronic disease
Phase 1 presentation at European Respiratory Society International Congress, October 1, 2019.
PRS-060
Asthma
Phase 1 data at SITC November 9, 2019 noted 2/18 response rate.
PRS-343
HER2-positive solid tumors
Phase 1 dose escalation data to be presented November 19, 2019.
PRS-343 and atezolizumab (Tecentriq)
HER2-positive solid tumors

Latest News

  1. Pieris Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    Company to Host an Investor Conference Call On Monday, November 11, 2019 At 8:00 AM ESTBOSTON, MA / ACCESSWIRE / November 11, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company

  2. Pieris Pharmaceuticals Presents Data Demonstrating Monotherapy Clinical Benefit with 4-1BB/HER2 Bispecific PRS-343 in Phase 1 Escalation Study at the Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting

    BOSTON, MA / ACCESSWIRE / November 9, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform

  3. Pieris Pharmaceuticals to Host R&D Event

    BOSTON, MA / ACCESSWIRE / November 7, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform

  4. Pieris Pharmaceuticals to Present Phase 1 Data for 4-1BB/HER2 Bispecific PRS-343 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

    BOSTON, MA / ACCESSWIRE / November 5, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform

  5. Pieris Pharmaceuticals Announces $32 Million Private Placement and Potential Funding Mechanism for PRS-060 Co-development Opt-in

    BOSTON, MA / ACCESSWIRE / November 4, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology

  6. Pieris Pharmaceuticals to Host Third Quarter 2019 Investor Call and Corporate Update on November 11, 2019

    BOSTON, MA / ACCESSWIRE / November 4, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform

  7. Pieris Pharmaceuticals and AstraZeneca Present Multiple Ascending Dose Phase 1b Data for Inhaled IL4-Rα Antagonist AZD1402/PRS-060 at the 2019 European Respiratory Society International Congress

    BOSTON, MA / ACCESSWIRE / September 26, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology

  8. Pieris Pharmaceuticals Announces Changes to Senior Management Team

    BOSTON, MA / ACCESSWIRE / September 3, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for

  9. Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences

    BOSTON, MA / ACCESSWIRE / August 29, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for